Assessment of the pharmacokinetic profile of novel s-triazine derivatives and their potential use in treatment of Alzheimer's disease
MetadataShow full item record
© 2016 Elsevier Inc. Aims The current treatment of Alzheimer's disease is purely symptomatic. Scientists are looking for new treatment options which could alter the course of the disease and improve the quality of life in patients with Alzheimer's disease. In this paper 14 novel s-triazine molecules have been evaluated for their lipophilicity. In addition docking study was carried out to evaluate acetylcholinesterase activity of these compounds. Main methods Lipophilicity was evaluated by RP HPTLC using 5 different mobile phases and obtained results were used in calculations of pharmacokinetic parameters - logBB, Ka and Pej. Multiple linear regression analysis was refined, taking account of molecular polarity (total polar surface area, TPSA) and molecular weight (Mw) descriptors. Appropriate QSAR models were developed. Docking studies were carried out using the Vina docking. Key findings Five out of fourteen compounds evaluated [5-10] are selected as the most promising compounds with satisfactory pharmacokinetic properties and good docking scores. Significance Compound 10 possesses the best combination of favourable pharmacokinetic characteristics (brain penetration, intestinal absorption) and capacity for acetylcholinesterase inhibition. Consequently this molecule should be further evaluated for potential therapeutic use in Alzheimer's disease.
Showing items related by title, author, creator and subject.
Bile acids as novel pharmacological agents: The interplay between gene polymorphisms, epigenetic factors and drug responsePavlovic, N.; Stanimirov, Bojan; Mikov, Momir (2017)© 2017 Bentham Science Publishers. Background: The field of bile acid research has become tremendously active. Bile acids have been shown to act as signaling molecules that are involved in many metabolic processes, but ...
Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle StudyFoster, Jonathan; Albrecht, Matthew; Savage, Greg; Lautenschlager, Nicola T.; Ellis, Kathryn A.; Maruff, Paul; Szoeke, Cassandra; Taddei, Kevin; Martins, Ralph; Masters, Colin L.; Ames, David (2013)Individuals who carry the apolipoprotein E ε4 polymorphism have an increased risk of late-onset Alzheimer’s disease. However, because possession of the ε4 allele confers an increased risk for the diagnosis of dementia, ...
Identification of novel peroxisome proliferator-activated receptor-gamma (PPAR[gamma]) agonists using molecular modeling methodKumar, Alan Prem (2014)Peroxisome proliferator-activated receptor-gamma (PPAR?) plays a critical role in lipid and glucose homeostasis. It is the target of many drug discovery studies, because of its role in various disease states including ...